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Allergic rhinitis: the eligible candidate 
to mite immunotherapy in the real world
Giorgio Ciprandi1*, Valentina Natoli2, Paola Puccinelli2, Cristoforo Incorvaia3 and Italian Cometa Study Group
Abstract 
As standard drug treatment of allergic rhinitis (AR) is not completely satisfactory, allergen immunotherapy (AIT) rep-
resents the only current treatment with the potential to modify the natural history. House dust mite (HDM) allergy is 
very common. The aim of the current experience was to describe the clinical profile of HDM-allergic patients with AR 
who received AIT in a real world model, such as allergy clinics. Globally, 239 patients (126 adults and 113 children; 107 
females and 132 males; mean age 21 years, age range 6–56 years) were evaluated. AIT was prescribed in 59 patients 
(24.7%), 44 adults (35%) and 15 children (13.3%). The current findings deriving from this real world multicentre study 
are consistent with previous investigations on HDM-AIT and define some clinical characteristics of the eligible candi-
date to this treatment. In fact, severity of ocular-nasal symptoms and over-use of symptomatic medications may typify 
the ideal candidate to HDM-AIT and SLIT was the preferred choice.
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Allergic rhinitis (AR) is a common illness that impairs 
quality of life and causes substantial economic burden 
[1]. There is evidence that AR may affect up to 40% of 
the general population [2]. Furthermore, the worldwide 
prevalence of AR is increasing. AR causes significant 
morbidity to affected individuals and has been estimated 
to account for relevant lost school or work days per 
year. Moreover, AR is a risk factor for asthma onset and 
worsening.
As standard drug treatment of AR is not completely 
satisfactory, allergen immunotherapy (AIT), either 
subcutaneous immunotherapy (SCIT) or sublingual 
immunotherapy (SLIT), represents the only current 
treatment with the potential to modify the course of 
allergic respiratory diseases by producing immuno-
logical and clinical tolerance to the causal allergen [3]. 
In this regard, allergy to house dust mites (HDM) is a 
very common cause of AR, mainly in children. There 
is some evidence that AIT to HDM is effective [4], but 
the findings are still conflicting. As AIT is a therapy 
characterized by long duration, expensive cost, and 
sometimes limited efficacy, there is the need to well 
define the characteristic of the ideal eligible candidate to 
HDM-AIT as recently appointed [5]. Karaman and col-
leagues performed a study aiming to investigate poten-
tial parameters useful in predicting the clinical response 
to AIT in HDM allergic children with asthma [6]. The 
authors enrolled 107 children mono-allergic to HDM: 
47 were treated with a 4–5 year course of SCIT, 67 were 
treated with medications alone and served as control. 
The only parameter predictive of a clinical response to 
AIT was the baseline serum total IgE level.
We believe that the issue concerning the definition 
of the ideal candidate to AIT is clinically relevant and 
deserves adequate consideration. In this regard, we report 
the outcomes provided by an Italian multi-centre obser-
vational survey conducted in 17 allergy clinics. The aim 
of the study was to describe the clinical profile of HDM-
allergic patients with AR who were allocated to AIT in 
a real world model, such as allergy clinics. Inclusion cri-
teria were: age between 6 and 60  years, mono-allergy to 
HDM, and written informed consent. Exclusion criteria 
were: different age, allergy to other allergens, previous 
AIT, severe psychiatric disorders. The study was approved 
by the Ethical Committee of each participating allergy 
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centre. The study was managed, monitored, and ana-
lysed by a Contract Research Organization (CD-Pharma 
Group, Milan, Italy) using electronic case report forms. 
Stallergenes Italia (Milan, Italy) sponsored the study.
Considered parameters were: AR duration, symptom 
periodicity, symptom severity perception assessed by 
visual analogue scale (VAS), asthma comorbidity, use of 
antihistamines and topical corticosteroids. χ2 test (with 
Fisher’s correction) and logistic regression were used 
(SAS system version 9.4) to analyze the data. Two hun-
dred thirty-nine patients (126 adults and 113 children; 
107 females and 132 males; mean age 21 years, age range 
6–56  years) were evaluated. All mite-allergic patients 
presented to clinic with AR symptoms. AIT was pre-
scribed in 59 patients (24.7%), 44 adults (35%) and 15 
children (13.3%). AIT prescription was decided consid-
ering the symptom burden, the medication use, and the 
willingness of patients.
The patients’ symptoms, although perennial, had a typ-
ical seasonal trend with an evident worsening during the 
fall-winter period (namely from October to March). This 
finding is consistent with previous studies that pointed 
out a periodicity of HDM presence at home, symptoms, 
drug use, and inflammatory features [7, 8]. Moreover, 
this finding might deserve interesting debate about the 
HDM-AIT schedule as recently argued [5].
AIT was prescribed only in about 25% of all screened 
patients, particularly only in 13% of paediatric subjects 
and about in 1/3 of adults. This outcome is quite sur-
prising because the main inclusion criterion was mono-
allergy to HDM, that is the optimal feature to indicate 
AIT. It is obvious that many factors may affect AIT pre-
scription, including allergists belief, patient persuasion, 
AIT duration, costs, misconceptions, etc. Concerning the 
route of administration of AIT, SLIT was prescribed in 
98% of patients. A mixture of Dermatophagoides farinae 
and D. pteronyssinus allergen extracts was used in 95% of 
prescriptions.
About the factors affecting the AIT choice, a series of 
parameters were evaluated. AR duration was longer in 
AIT-treated group than in other patients (7.2 vs. 6 years). 
Asthma was present in 41% of AIT-treated patients and 
in 34% of remaining patients. Interestingly, cough was 
the most relevant asthma symptom reported in AIT 
group, whereas breathlessness was most frequent in AIT-
untreated patients. The severity of both conjunctival and 
nasal symptom perception was greater in AIT-treated 
patients. VAS for ocular symptoms were 3.95 and 2.87 
respectively (p = 0.01); VAS for nasal symptoms was 7.9 
and 5.9 respectively (p = 0.0001). Consistently, conjunc-
tivitis co-morbidity was more frequent in AIT-treated 
group (p = 0.002) as well as nasal polyps (p = 0.02).
The significant predictive factors were: use of antihis-
tamines (OR 1.3; CI 1.03–1.31; p = 0.01), use of topical 
corticosteroids (OR 1.3; CI 1.02–1.29; p  =  0.02), and 
rural residence (OR 4.4; CI 1.32–15.1; p =  0.02). These 
outcomes underline that the patient candidate to HDM-
AIT presents a clinical feature quite different from other 
HDM patients. Obviously, the present study was per-
formed in real life and some factors might interfere with 
results. For example, the above considered aspects (e.g. 
duration, cost, etc.) may influence the rate of AIT pre-
scription. However, it is apparent that AIT candidates 
generally present a more severe clinical profile, mainly 
concerning ocular and nasal symptom and medica-
tion use. Therefore, AIT was preferentially prescribed 
in patient with moderate-to-severe AR. Noteworthy, 
this aspect is consisting with the evidence that AIT is 
more effective in patients complaining more bother-
some symptoms. In fact, a study reported that patients 
with severe symptoms were more responsive to AIT 
than patients with mild symptoms [9]. Rural residence 
is a singular outcome, that probably might be correlated 
with greater humidity present in country areas. Moreo-
ver, there is evidence that urban children may be exposed 
to protective factors so experiencing potentially milder 
HDM-AR [10].
In conclusion, the current findings deriving from this 
real world multicentre study are consistent with previ-
ous investigations on HDM-AIT [4], and define some 
clinical characteristics of the eligible candidate to this 
treatment. In fact, severity of ocular-nasal symptoms 
and over-use of symptomatic medications may typify 
the ideal candidate to HDM-AIT and SLIT was the pre-
ferred choice.
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